Vifor Pharma Management Ltd

Vifor Pharma Management Ltd

Flughofstrasse 61 P.O. Box 8152 Glattbrugg Switzerland

Korsuva & Kapruvia

Korsuva & Kapruvia

KORSUVA™/ KAPRUVIA®

Kapruvia® (EU) / KorsuvaTM (US) is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.

CHRONIC KIDNEY DISEASE ASSOCIATED PRURITUS THE DISEASE
Moderate-to-severe CKD-associated Pruritus (CKD-aP) is an intractable systemic itch condition that impacts up to 40% of dialysis patients around the world.2,3 It is associated with poor quality of life, reduced social interactions and depression. It is also identified as an independent predictor of mortality among hemodialysis patients, with current treatment options which are not indicated for the treatment of CKD-aP, linked to limited efficacy and/or unfavorable tolerability.

Korsuva™/ Kapruvia® (difelikefalin), developed by Cara Therapeutics, Inc., is a peripherally restricted kappa opioid receptor (KOR) agonist, targeting KORs on peripheral sensory neurons and immune cells.

Kapruvia® (EU) / KorsuvaTM (US) is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.

The approval was based on positive data from two pivotal phase-III trials – the KALM-1 study conducted in the US3, and the global KALM-2 study, including supportive data from an additional 32 clinical studies.
These studies showed that treatment with Korsuva™/ Kapruvia® injection resulted in clinically meaningful improvements in pruritus severity and in pruritus-related quality of life components and was found to be generally well tolerated in patients with moderate-to-severe CKD-associated Pruritus. For more information about Korsuva in the US, please visit the dedicated site 

How does Kapruvia® work?

Difelikefalin, the active substance in Kapruvia®, is a kappa opioid receptor agonist that bind to receptors (targets) on nerves and immune cells involved in controlling itching and inflammation. By binding to the receptors (called kappa opioid receptors), difelikefalin activates them, reducing inflammation that could lead to itchiness and decreasing the signals that lead to the feeling of itchiness itself.
Kapruvia® is delivered as an IV injection at the end of a haemodialysis procedure. It is given three times per week and the dose depends on the patient’s weight.

Product Enquiry

SSL Secure Connection